Fennec Pharmaceuticals Inc.
General ticker "FENC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $204.1M (TTM average)
Fennec Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 36.1%.
Estimated limits based on current volatility of 3.5%: low 6.11$, high 6.63$
Factors to consider:
- Total employees count: 29 (-19.4%) as of 2023
- Top business risk factors: Significant losses, Dependence on PEDMARK success, Regulatory and compliance, Supply chain disruptions, Intellectual property risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.07$, 11.82$]
- 2026-12-31 to 2027-12-31 estimated range: [6.52$, 12.51$]
Financial Metrics affecting the FENC estimates:
- Positive: with PPE of -27.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5.67 <= 0.07
- Positive: Inventory ratio change, % of 0.63 <= 0.80
- Positive: Investing cash flow per share per price, % of 0 > -0.65
- Positive: 42.60 < Shareholder equity ratio, % of 50.03 <= 64.25
Short-term FENC quotes
Long-term FENC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $21.25MM | $47.54MM | $45.42MM |
| Operating Expenses | $34.02MM | $44.97MM | $52.29MM |
| Operating Income | $-12.77MM | $2.57MM | $-6.86MM |
| Non-Operating Income | $-3.20MM | $-2.64MM | $-3.41MM |
| Interest Expense | $3.39MM | $4.07MM | $2.18MM |
| R&D Expense | $0.06MM | $0.31MM | $0.25MM |
| Income(Loss) | $-15.97MM | $-0.07MM | $-10.27MM |
| Taxes | $0.00MM | $0.36MM | $0.00MM |
| Profit(Loss)* | $-16.05MM | $-0.44MM | $-10.27MM |
| Stockholders Equity | $-11.62MM | $-5.87MM | $35.05MM |
| Inventory | $2.16MM | $1.06MM | $1.56MM |
| Assets | $26.86MM | $44.95MM | $70.07MM |
| Operating Cash Flow | $-17.14MM | $26.98MM | $-12.47MM |
| Financing Cash Flow | $6.64MM | $-13.62MM | $22.63MM |
| Earnings Per Share** | $-0.60 | $-0.02 | $-0.36 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.